Babies need healthy bacteria

Probiotics must meet three criteria

Prior to birth, babies have little or no bacteria in their gut. Bacteria begin to colonise the gut soon after birth. While these bacteria can come from a variety of sources, breast milk plays an important role in the colonisation process.Breast milk is the ideal way to feed a baby, but when an infant is unable to be breastfed then a suitable infant formula is required. Formula fed infants need healthy bacteria (or probiotics) to help colonise their gut. The right probiotics can help improve intestinal function as well as aid immune system development and help prevent allergies. Fonterra has developed two probiotic strains, sourced from dairy cultures, which meet the FAO and WHO requirements of probiotics and deliver proven health benefits for infants.

ProtectionSome probiotic strains can

help prevent pathogenic bacteria from gaining

nutrient space in the gut, inhibiting the ability for

them to grow and thrive. Surestart™’s probiotic strains

have been shown to reduce incidence of respiratory infections, pneumonia, fever and some other

childhood illnesses. (see research Trial A and Trial C)

Supporting immunitySelect probiotic strains may help balance the immune system by enhancing the activity of immune cells associated with protection against pathogens and promoting tolerance to non-threatening antigens. In human trials, consumptionof Surestart™’s probiotic strains have consistently shown immune enhancing attributes.(see research Trial A, Trial B and Trial C)

Joint FAO/WHO Expert Consultation on Evaluationof Health and Nutritional Properties of Probiotics inFood including Powder Milk with Live Lactic AcidBacteria, 1-4 October 2001

Provide no threat to human health or wellbeing.

Clearly defined and demonstrable health benefits.

Maintains viability in the product throughout shelf-life and survivesthe harsh environment of the intestine.

Safe Effective Stable

Probiotics are “livemicro-organisms which, when administered in adequate amounts, confer a health benefit on the host.”

Product Summary: SureStart™ BifidoB 019

Fonterra supports the aim and intent of WHO Code for the Marketing of Breast milk Substitutes. The WHO states that breast milk is the ideal source of nutrition for infants and that breast milk substitutes are safe & nutritious alternatives to breast milk for infants whose mothers cannot or choose not to breastfeed.

VERSION03.JANUARY/2018

The information in this brochure is designed to give a brief overview of the nature, characteristics and potential benefits of our ingredients as at the date of preparation. It does not constitute representations or warranties as to such characteristics, the functionality, product claims or potential applications of our ingredients and you must assure yourself of these matters having regard to our detailed product specifications, your specific circumstances and applicable market requirements.

Effective:Research trials with Bifidobacterium lactis (SureStart™ BifidoB 019)

Trial A

Trial B

Source: Sazawal et al. (2010) PLoS, One. 5:e12164. Sazawal et al. (2010) JPGN 51:341-6

Trial B Immunity: 1 year trial with 600 children demonstrated lower rates of antibiotic consumption amongst children taking BifidoB 019 as well as lower rates of anaemia and iron deficiency.

Trial A Protection: 1 year trial with 600 children demonstrated lower incidence of fever and childhood illnesses.

∙ 35% reduction in incidence ofsevere and acute lowerrespiratory infections.

∙ 24% reduction in incidence ofpneumonia.

∙ 21% reduction in incidence ofdysentery episodes.

∙ 16% reduction in days/durationwith severe illness.

∙ 5% reduction in days/durationwith high fever.

Children taking BifidoB 019 showed:

Source: Sazawal et al. (2010) PLoS , One. 5:e12164. Sazawal et al. (2010), JPGN 51:341-6, Dekker et al, (2009).

BifidoB 019 + GOS (n=230)

0 10 20 30

p = 0.01

% Infants Anaemic and iron deficient

Day

s w

ith

seve

re il

lnes

s

Control

BifidoB 019

p = 0.03

less than 24 months

greater than 24 months

p = 0.05

Control (n=213)

400

350

300

250

200

150

100

50

0

2

Effective:Research trials with Bifidobacterium lactis (SureStart™ BifidoB 019)

Conclusion SureStart™ BifidoB 019 deliver a range of clearly defined and demonstrable health benefits for formula fed infants. This includes reduced incidence of common childhood illnesses such as respiratory infection, decreased severity of illness, and a lower rate of prescribed medication.

Trial C Immunity & Protection: 12 week trial with 192 infants aged 6-12 months, showed that supplementation with SureStart™ BifidoB 019 resulted in reduced rates of physician confirmed infections and need for prescribed antibiotic or antiviral medication. Source: Dekker et al 2012

Percentage of Infants with physician- confirmed respiratory tract infections in groups treated with BidifoB 019 vs. LactoB 001 vs. Placebo.

Percentage of Infants with prescribed medication in groups treated with BidifoB 019 vs. LactoB 001 vs. Placebo

BifidoB 019 significantly reduced reported respiratory tract infections.Source: Fisher’s Exact Test, BifidoB 019 vs. placebo

Trial C

Trial C

BifidoB 019n=64

LactoB 001n=64

Placebon=64

*P= 0.028

Per

cent

age

25

20

15

10

5

0

BifidoB 019n=64

LactoB 001n=64

Placebon=64

*P= 0.0013

Per

cent

age

10

8

6

4

2

18

16

14

12

0

Trial C

Trial C

3

Talk to the paediatric dairy ingredient expertsWe’re passionate about sharing our deep dairy expertise to help you grow your business. Talk to us today about your paediatric dairy ingredient needs.

To find out more or to purchase our ingredients please visit surestartnutrition.com

World-leading paediatric nutrition for a trusted start to life.